VANDA PHARMACEUTICALS INC. Revenue, Net (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Revenue, Net (Deprecated 2018-01-31) of $8.71 million for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Income Statement
us-gaap:SalesRevenueNet · last filed 2013-11-08
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $8.71M, a 5.08% increase year-over-year.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $8.32M, a 0.70% decline year-over-year.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2013-03-31 was $8.07M, a 0.90% decline year-over-year.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2012-12-31 was $7.92M, a 5.38% decline year-over-year.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for fiscal 2012 was $32.73M, a 4.66% increase from fiscal 2011.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for fiscal 2011 was $31.27M, a 12.43% decline from fiscal 2010.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for fiscal 2010 was $35.71M, a 685.16% increase from fiscal 2009.
- VANDA PHARMACEUTICALS INC. revenue, net (deprecated 2018-01-31) for fiscal 2009 was $4.55M.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2013-09-30 | $8.71M 10-Q · filed 2013-11-08 | $17.03M derived: sum of 2 quarters · filed 2013-11-08 | $25.10M 10-Q · filed 2013-11-08 | $33.02M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-06-30 | $8.32M 10-Q · filed 2013-07-31 | $16.39M 10-Q · filed 2013-07-31 | $24.31M derived: sum of 3 quarters · filed 2013-07-31 | $32.59M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-03-31 | $8.07M 10-Q · filed 2013-05-10 | $15.99M derived: sum of 2 quarters · filed 2013-05-10 | $24.28M derived: sum of 3 quarters · filed 2013-11-08 | $32.65M derived: sum of 4 quarters · filed 2013-11-08 |
| 2012-12-31 | $7.92M 10-K · filed 2013-02-26 | $16.21M derived: sum of 2 quarters · filed 2013-11-08 | $24.59M derived: sum of 3 quarters · filed 2013-11-08 | $32.73M 10-K · filed 2013-02-26 |
| 2012-09-30 | $8.29M 10-Q · filed 2013-11-08 | $16.67M derived: sum of 2 quarters · filed 2013-11-08 | $24.81M 10-Q · filed 2013-11-08 | $33.18M derived: sum of 4 quarters · filed 2013-11-08 |
| 2012-06-30 | $8.38M 10-Q · filed 2013-07-31 | $16.52M 10-Q · filed 2013-07-31 | $24.89M derived: sum of 3 quarters · filed 2013-07-31 | $32.86M derived: sum of 4 quarters · filed 2013-07-31 |
| 2012-03-31 | $8.14M 10-Q · filed 2013-05-10 | $16.51M derived: sum of 2 quarters · filed 2013-05-10 | $24.48M derived: sum of 3 quarters · filed 2013-05-10 | $31.91M derived: sum of 4 quarters · filed 2013-05-10 |
| 2011-12-31 | $8.37M 10-K · filed 2013-02-26 | $16.34M derived: sum of 2 quarters · filed 2013-02-26 | $23.77M derived: sum of 3 quarters · filed 2013-02-26 | $31.27M 10-K · filed 2013-02-26 |
| 2011-09-30 | $7.97M 10-K · filed 2013-02-26 | $15.40M derived: sum of 2 quarters · filed 2013-02-26 | $22.90M 10-Q · filed 2012-11-08 | $30.65M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $7.43M 10-K · filed 2013-02-26 | $14.93M 10-Q · filed 2012-08-03 | $22.68M derived: sum of 3 quarters · filed 2013-02-26 | $29.93M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $7.50M 10-K · filed 2013-02-26 | $15.25M derived: sum of 2 quarters · filed 2013-02-26 | $22.50M derived: sum of 3 quarters · filed 2013-02-26 | $30.79M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $15.00M derived: sum of 2 quarters · filed 2013-02-26 | $23.29M derived: sum of 3 quarters · filed 2013-02-26 | $35.71M 10-K · filed 2013-02-26 |
| 2010-09-30 | $7.25M 10-Q · filed 2011-11-07 | $15.54M derived: sum of 2 quarters · filed 2011-11-07 | $27.96M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $8.29M 10-Q · filed 2011-08-05 | $20.71M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $4.55M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |